Enjoyed presenting at #ESCCongress in London ✨SCORED - Sotagliflozin improves HF outcomes with increasing benefit for longer diabetes duration ✨REDUCE-IT sdLDL-C - icosapent ethyl improves CV outcomes irrespective of baseline small dense LDL ✨NHANES V1P - Enrollment

Incredible to see LLMs already taking center stage in cardiology. It is an honor to be at the forefront of this exciting movement! Thrilled that our RCT has been selected for presentation at #AHA24 as an #LBCT/#FS. Cannot wait to share our findings with the community!

How much🪑 is "too much" and why does this matter? Thrilled to share our #simpub (tinyurl.com/4andw2cm) in JACC Journals that addresses this Q. This work will be presented at #AHA24!

Heading to Chicago for #AHA2024! Excited to present our MAPS-LLM trial as an #LBCT/#FS. Join us on Saturday for an exciting reveal of the results—we can’t wait to share! AJ Blood, MD, MS

Can’t wait to share this data! Going to be an exciting session.

Join us for #AHA2024 LBCT / Featured Science on Health Tech & Clinical Trials tomorrow Looking forward to sharing our work on natural language processing for event adjudication in DELIVER trial And learning from Rohan Khera Alexis Beatty @KPHeartDoc Ozan Unlu and panel

Can health tech 💻like NLP and LLMs help with pragmatic use of clinical trials? Let’s find out! #AHA24

Thrilled to welcome this outstanding group of trailblazers to the BWH Cardiology family, we are so excited!! 🤩🤩🤩

Germline monogenic and polygenic risk are associated with acute coronary syndromes presentation, severity and burden of atherosclerosis, and risk of repeat angiogram, revascularization, and in-stent restenosis. @ozanunlumd ja.ma/42ogBEG

Excited to share our group's publication out today - the MAPS-LLM trial. lnkd.in/eBAkEwS5. The study, now out in JAMA, showcased the effectiveness of our Generative-AI tool in enhancing screening efficiency and clinical trial enrollments. In a blinded RCT, the team

AI-assisted patient screening improved the rate of eligibility determination and enrollment compared with manual screening in a heart failure trial. ja.ma/417cxXc AJ Blood, MD, MS @ozanunlumd

I am incredibly grateful to be part of this team! Excited to transform the way we conduct clinical trials to accelerate the delivery of novel therapies to our patients more efficiently.

In a new study, researchers AJ Blood, MD, MS and @ozanunlumd from Brigham and Women's Hospital and their colleagues found that AI screening for heart failure in clinical trials sped up enrollment. The study was published in JAMA. Read more: buff.ly/4bdRG8V buff.ly/41wkFBC

Tomorrow at SXSW, our very own Sandy Aronson joins an expert panel on “The Power of GenAI to Transform the Future of Medical Research.” From accelerating drug development to improving patient outcomes, AI is reshaping clinical trials! 🔗 schedule.sxsw.com/2025/events/PP… #AIwithCare

Great interview by AJ Blood, MD, MS about our work on using LLMs for patient identification and clinical trial recruitment!

AI-assisted patient screening improved the rate of eligibility determination and enrollment compared with manual screening in a heart failure trial. ja.ma/43tLcBh AJ Blood, MD, MS @ozanunlumd

Dear OpenAI, can we do something about the color choice in your graphs? I love your work but this is painful!

This has been such a transformative experience! So grateful for everyone who have taught and mentored me throughout this training. I feel so lucky to be part of this community and look forward to the next steps!